Loading...
•
Dec 31, 2024
C4 Therapeutics Q4 2024 Earnings Report
C4 Therapeutics reported its financial results for the fourth quarter and full year ended December 31, 2024.
Key Takeaways
C4 Therapeutics reported increased revenue for Q4 2024, primarily driven by new collaborations. The company's net loss remained relatively flat compared to the prior year, and its cash position is expected to provide a runway into 2027.
Revenue from collaboration agreements increased to $5.177 million in Q4 2024 from $3.261 million in Q4 2023.
Net loss for Q4 2024 was $34.573 million, a slight improvement from $34.754 million in Q4 2023.
Cash, cash equivalents, and marketable securities stood at $267.263 million as of December 31, 2024, providing a runway into 2027.
Research and development expenses increased to $32.513 million in Q4 2024, reflecting ongoing clinical trial advancements.
Revenue by Segment
Forward Guidance
C4 Therapeutics expects its cash, cash equivalents, and marketable securities as of December 31, 2024, to fund its operating plan into 2027. The company is focused on advancing its clinical programs and operationalizing the next phase of cemsidomide development.
Positive Outlook
- Planning activities are ongoing for the next phase of cemsidomide clinical development in Multiple Myeloma and Non-Hodgkin's Lymphoma, with trials expected to initiate in early 2026.
- CFT1946 Phase 1/2 trial continues to progress across multiple cohorts, with data in melanoma and colorectal cancer expected in the second half of 2025.
- Cemsidomide Phase 1 dose escalation data in MM and NHL expected in the second half of 2025.
- Open expansion cohort(s) in PTCL as part of the current Phase 1/2 trial expected in the second half of 2025.
- CFT1946 monotherapy Phase 1 dose escalation in BRAF V600 mutant solid tumors expected to complete in the first half of 2025.
Challenges Ahead
- The company did not report any specific negative forward guidance or risks in the provided text beyond general forward-looking statement disclaimers.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...